Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: a randomized, double-blind, controlled trial with loratadine and placebo

Background and objectives: Allergic rhinitis is a global health concern of increasing prevalence that can impact quality of life and work and school performance of affected individuals. Antihistamines are recommended as the first-line treatment. This randomized, controlled trial aimed to investigate the effects of rupatadine in adult subjects with perennial allergic rhinitis. Methods: We randomly assigned 283 patients to receive placebo (n = 69), loratadine 10 mg (n = 70), rupatadine 10 mg (n = 73) or rupatadine 20 mg (n = 71). The study design was double blind and treatment was continued for 4 weeks. Subjective assessment of symptoms (reflective evaluation) was recorded by patients in a diary card. The primary end point was the percentage of days where the score of the most severe symptom was less than or equal to one (Pdmax1). Furthermore, the change from baseline in the severity of total symptom score and nasal symptom score were recorded, and the investigator and patient global assessments were evalua...

[1]  M. Rottem.  [Allergic rhinitis and its impact on asthma]. , 2010, Harefuah.

[2]  I. Agache,et al.  A 12‐week placebo‐controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis , 2008, Allergy.

[3]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[4]  J. Bousquet,et al.  Rupatadine in allergic rhinitis and chronic urticaria , 2008, Allergy.

[5]  C. Akdis,et al.  Histamine in Allergic Inflammation and Immune Modulation , 2005, International Archives of Allergy and Immunology.

[6]  S. Durham,et al.  Epidemiological characterization of the intermittent and persistent types of allergic rhinitis , 2005, Allergy.

[7]  S. Durham,et al.  Prevalence and rate of diagnosis of allergic rhinitis in Europe , 2004, European Respiratory Journal.

[8]  C. Picado,et al.  Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study , 2004, Allergy.

[9]  J. García-Rafanell,et al.  Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. , 2003, Drugs of today.

[10]  C. Bachert,et al.  Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  R. Leurs,et al.  H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  C. Bachert,et al.  The role of histamine in allergic disease: re‐appraisal of its inflammatory potential , 2002, Allergy.

[13]  D. Wang,et al.  Pathogenic Mechanisms Underlying the Clinical Symptoms of Allergic Rhinitis , 2000, American journal of rhinology.

[14]  M. Yokota,et al.  Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflammatory, and atherosclerotic diseases. , 1998, Japanese circulation journal.

[15]  L. Petersen,et al.  Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade. , 1997, The Journal of allergy and clinical immunology.

[16]  T. Haahtela,et al.  Asthma and Allergic Rhinitis among Finnish Adolescents in 1977–1991 , 1995, Scandinavian journal of social medicine.

[17]  P. Venge,et al.  Soluble markers of allergic inflammation , 1994, Allergy.

[18]  G. Aversa,et al.  Induction of isotype switching and Ig production by CD5+ and CD10+ human fetal B cells. , 1992, Journal of immunology.

[19]  L. Ödkvist,et al.  A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis , 1990, Allergy.

[20]  F. Horak,et al.  Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis. , 1989, The Journal of allergy and clinical immunology.

[21]  E. Arnáiz,et al.  Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  E. Arnáiz,et al.  Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. , 2005, Journal of investigational allergology & clinical immunology.

[23]  I. Izquierdo,et al.  A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. , 2004, Journal of investigational allergology & clinical immunology.

[24]  G. Zimmerman,et al.  Platelet-activating factor and related lipid mediators. , 2000, Annual review of biochemistry.

[25]  J. García-Rafanell,et al.  Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  E. Juniper,et al.  International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. , 1994, Allergy.